2021: A Unique World Hepatitis Day
COVID-19 & Sports
COVID-19 & Sports
COVID-19 & Sports

Published Work
From observational studies to clinical trials, the VIDC research team shares our findings with the medical community at international conferences.
​
Visit us at an upcoming conference >


- Feb 28, 2020
Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection among active drug users

- Feb 28, 2020
Sofosbuvir/velpatasvir (S/V) for the treatment of chronic HCV in active drug users: the CHIME study

- Feb 28, 2020
Overdose events among active drug users successfully treated for HCV: the impact of homelessness.
- Feb 11, 2020
Glecaprevir/pibrentasvir+sofosbuvir: An optimal retreatment strategy in the setting of HCV NS5A ...
- Dec 16, 2019
Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C

- Nov 8, 2019
Effectiveness of sofosbuvir/velpatasvir and elbasvir/grazoprevir for the treatment of HCV genotype 1

- Nov 8, 2019
Long-term follow-up of people who use drugs (PWUD) following successful HCV therapy...
- Oct 14, 2019
Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C
- Jul 17, 2018
Diagnosis and treatment of hepatitis C virus infection: a tool for engagement with people who inject